Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis
Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to
assess the efficacy of activated recombinant human factor VII in the treatment of refractory
haemorrhagic cystitis (HC) following chemotherapy.